Vision & Mission


Helping patients with safe, effective biologic drugs

Our aim and vision is to enable broad access to high quality, highly competitive biopharmaceuticals for the treatment of serious diseases.


Medicines of the future


Biosimilars are the drugs of the future. Through their proven efficacy, cost efficiency and high standard of quality, Biosimilar medicines are already making a major contribution towards enabling patient access to effective medical treatments.

Through our biosimilars, we will help not only patients around the world but also help to ease the financial strains on the world’s healthcare systems.

“Biological medicines are … complex and can be very expensive and time consuming to develop. This can limit patients’ access to such medicines, and can make it difficult for the healthcare system to afford them. Biosimilar medicines can improve patient access to such treatments.”

European Commission, Biosimilar Medicines: Information for Patients, 2016

Profitable and sustainable growth


Already today, Formycon is a significant player in the biosimilars market segment. Our goal now is to further strengthen this position and to become, as a leading independent developer of Biosimilar medicines, a major and truly global player.

Our strategic focus is on the “third wave” of biosimilars, meaning follow-on drugs to compete with established blockbuster biopharmaceuticals for which patent protection will begin expiring from the year 2020 onwards. Because Formycon began targeting these products at an early stage, the company is now uniquely positioned to lead the way into these new markets.

“The market is well positioned to achieve a robust growth in the coming decade … Based on a very comprehensive analysis, we have projected the market to be worth USD 32 billion worldwide by 2025.”

Research and Markets,Global Biosimilars Market Report, 2015 – 2025

Strong pipeline


Building on the specialized expertise and long experience of our team, as well as our successful established track record in biosimilar development, we are able to evaluate further potential and promising biosimilar candidates for our pipeline.

Because Formycon spans the entire value chain – from early analysis to technical-pharmaceutical development and clinical trials, all the way through to preparation and submission of dossiers for regulatory approval – we are able to offer our partners a complete, end-to-end drug development concept.

“In the coming year, biosimilars will play an increasingly important role in the treatment of serious diseases ... and in keeping our health care system affordable.”

German Federal Ministry of Health, Report on Results of Pharmaceutical Dialog, 2016

Latest news


Formycon confirms BLA-Submission Strategy and Timeline for its Lucentis(R)* Biosimilar-Candidate FYB201 following consultation with the FDA

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its licensing partner Bioeq AG ("Bioeq") confirm the planned timeline for resubmission of the Biologics License Application ("BLA") for their Lucentis(R) biosimilar candidate FYB201 following a successful pre-BLA interaction with the U.S....

Formycon receives positive Scientific Advice from Paul-Ehrlich-Institute for the COVID-19 Drug FYB207 and assures GMP Manufacturing Capacities

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) has received the consent from the Paul-Ehrlich-Institute (PEI) regarding the proposed development concept for its innovative SARS-CoV-2 blocker FYB207. As result of the Scientific Advice, the Federal Institute for Vaccines and Biomedicines...

Formycon’s Scientific Collaboration Partners present FYB207 Results at International Keystone Symposium

Munich - Formycon (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today announced that its academic partners of the Technical University of Munich, present results on Formycon's COVID-19 drug (FYB207).


¹ Lucentis is a registered trademark of Genentech, Inc
² Stelara is a registered trademark of Johnson & Johnson
³ Eylea is a registered trademark of Regeneron Pharmaceuticals, Inc.